China Biotech Services Holdings Ltd. has announced its unaudited interim condensed consolidated results for the six months ended June 30, 2025. The company reported a revenue increase to HK$38.872 million from HK$32.449 million in the corresponding period of 2024. The revenue growth was primarily driven by the provision of insurance brokerage services, which generated HK$22.640 million, a significant rise from HK$12.255 million in the previous year. Despite the increase in revenue, the company recorded a loss before tax of HK$37.159 million, compared to a gross loss of HK$3.107 million last year. The segment analysis revealed that the medical and health-related services, including medical laboratory testing and health check services, recorded a revenue of HK$16.164 million, down from HK$19.729 million in 2024. Significant expenses included selling and distribution costs of HK$3.630 million and research and development costs amounting to HK$5.965 million. Other income and gains, net, improved significantly to HK$21.728 million from a loss of HK$26.460 million in the same period last year. The company did not provide any specific outlook or guidance in this announcement.